Nurix Therapeutics (NRIX) EBT Margin (2019 - 2025)
Historic EBT Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 576.13%.
- Nurix Therapeutics' EBT Margin fell 1354400.0% to 576.13% in Q4 2025 from the same period last year, while for Nov 2025 it was 314.0%, marking a year-over-year increase of 403600.0%. This contributed to the annual value of 314.0% for FY2025, which is 403600.0% up from last year.
- Latest data reveals that Nurix Therapeutics reported EBT Margin of 576.13% as of Q4 2025, which was down 1354400.0% from 1094.77% recorded in Q3 2025.
- Over the past 5 years, Nurix Therapeutics' EBT Margin peaked at 79.14% during Q2 2023, and registered a low of 1094.77% during Q3 2025.
- For the 5-year period, Nurix Therapeutics' EBT Margin averaged around 399.66%, with its median value being 379.17% (2024).
- As far as peak fluctuations go, Nurix Therapeutics' EBT Margin skyrocketed by 4119600bps in 2023, and later tumbled by -7065100bps in 2025.
- Over the past 5 years, Nurix Therapeutics' EBT Margin (Quarter) stood at 509.17% in 2021, then tumbled by -35bps to 688.74% in 2022, then soared by 60bps to 276.77% in 2023, then tumbled by -59bps to 440.69% in 2024, then tumbled by -31bps to 576.13% in 2025.
- Its EBT Margin stands at 576.13% for Q4 2025, versus 1094.77% for Q3 2025 and 96.93% for Q2 2025.